MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Composite Materials for Bone Replacement

Korea Health Industry Development Institute
, the composite materials of this technique can be applied to fill bone defect and replace, since they retain the excellent physical property.

Mechanism of action

□Materials for bone replacement with excellent physical property, □Little Toxicity anf High Biocompatibility ,□Osteo-conductive inorganic material modified on the surface by an polymerization inhib ,

Full description

Technology Platform

The core technology of YESBIO is to provide Composite Materials for Bone Replacement.  The Composite Materials according to this technique, maximize the merits of organic material and inorganic material and minimizes their demerits.  In detail, the organic material has the maintenance of shape and the adhesive property and the inorganic material has the osteo-conductivity on new bones.  Therefore, the composite materials of the present invention can be applied to fill bone defect and replace, since they retain the excellent physical property.

Background and unmet needs: Bone researches are investigated a lot in overall medical fields including dentistry and orthopedic surgery.  Materials for bone replacement should have excellent tissue compatibility, be available in unlimited quantities, be easy contoured, retain stable shape over time, become ingrowth or replaced by living tissue. However, there is no material suitable for this use yet.

In previous studies, the composite material combining inorganic material and organic material is being described.  Raveh et al. have investigated to manufacture the composite material by using bioglass and Bis-GMA(2,2-bis[4(2-hydroxy-3-methacryloxypropoxy) phenyl]propane).  However, this composite material is not absorbed completely and brings about adverse actions after operated.  Especially, it is recognized as a foreign body due to lacking in adhesiveness.

In addition, Wright et al. have contrived to prepare a composite material by mixing reinforcing fiber and PMMA.  This composite material may disperse the heat of polymerization from PMMAs to prevent bone necrosis during the reaction.  Nevertheless, this material has a too low adhesive strength as a glue to be applied actively.

Discovery and Achievements: Composite Materials for Bone Replacement of YESBIO has been developed on the basis of findings that novel methods for mixing β-TCP with CA without chemical modification.

First, β-TCP is encapsulated with other biodegradable polymers on the surface in order to facilitate their combination, even maintaining its physical property. 

Second, β-TCP is encapsulated on the surface with acids to be neutralized or acidified, since its surface is weakly basic.  This procedure makes these materials combined easily without additional components.

The organic material has the maintenance of shape and the adhesive property and the inorganic material has the osteo-conductivity on new bones.  Therefore, the composite materials of this technique can be applied to fill bone defect and replace, since they retain the excellent physical property. In Fig. 1, the composite materials represents significant physical property.

Development status

Early Stage

Patent information

 

Country

Status

Patent, Publication or Appln. No.

Korea

Patented

10-2005-0048061

U.S.A.

Patented

11/296944

 

 

 

Type of business relationship sought

technology transfer, or non-exclusive or exclusive licensing agreement

Company details

Korea Health Industry Development Institute

KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Industry sector
Academic/Research / Medical device
Therapeutic target
Hospital and Surgery

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us